Effect of radiotherapy for rectal cancer on ovarian androgen production. BJS 2019; 106: 267-275.
Published: 12th September 2018
Authors: J. Segelman, C. Buchli, A. Svanström Röjvall, P. Matthiessen, S. Arver, M. Bottai et al.
The impact of radiotherapy (RT) for rectal cancer on ovarian androgen production is unknown. The aim was to examine the effect of RT for rectal cancer on androgen levels in non‐oophorectomized women and the association with female sexual desire.
This prospective cohort study included women who had surgery for rectal cancer with or without RT. Serum testosterone, free testosterone, androstenedione and dehydroepiandrosterone sulphate (DHEA‐S) levels were assessed at baseline, after RT and 1 year after surgery. Sexual desire was assessed by means of the Female Sexual Function Index.
Twenty‐seven participants had surgery alone (RT– group) and 98 had preoperative RT and surgery (RT+ group). During the first year after surgery, median serum testosterone and free testosterone levels decreased from 0·6 (range 0·1–3·6) to 0·5 (0·1–2·3) nmol/l (P < 0·001) and from 9·1 (1·6–45·8) to 7·9 (1·4–22·7) pmol/l (P < 0·001) respectively in the RT+ group, but did not change in the RT– group. Longitudinal regression analysis confirmed a decrease in testosterone and free testosterone after RT. The adjusted change in androstenedione and DHEA‐S was not significant in any group. The mean change in testosterone (odds ratio (OR) 2·74, 95 per cent c.i. 1·06 to 7·11; P = 0·038), free testosterone (OR 1·08, 1·02 to 1·15; P = 0·011), androstenedione (OR 1·52, 1·07 to 2·16; P = 0·019) and DHEA‐S (OR 0·49, 0·27 to 0·89; P = 0·019) was related to change in sexual desire.
RT decreased levels of androgens predominantly derived from the ovaries, whereas androgens of mainly adrenal origin remained unchanged. Reduction in ovarian androgens may be associated with reduced sexual desire.Full text
You may also be interested in
Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Authors: T. Akiyoshi, N. Tanaka, K. Kiyotani, O. Gotoh, N. Yamamoto, K. Oba et al.
BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Authors: J.‐B. Bachet, N. Moreno‐Lopez, L. Vigano, U. Marchese, M. Gelli, L. Raoux et al.
Authors: Z. Lakkis, D. Vernerey, D. Mege, J.‐L. Faucheron, Y. Panis, J.‐J. Tuech et al.
Propensity score‐matched analysis of oncological outcome between stent as bridge to surgery and emergency resection in patients with malignant left‐sided colonic obstruction.
Authors: F. J. Amelung, W. A. A. Borstlap, E. C. J. Consten, J. V. Veld, E. E. van Halsema, W. A. Bemelman et al.
Authors: A. Zaborowski, A. Stakelum, D. C. Winter
Association between surgeon special interest and mortality after emergency laparotomy. BJS 2019; 106: 940-948.
Authors: H. Boyd‐Carson, B. Doleman, P. J. J. Herrod, I. D. Anderson, J. P. Williams, J. N. Lund et al.
Incidence and lifetime risk of hospitalization and surgery for diverticular disease. BJS 2019; 106: 930-939.
Authors: F. Sköldberg, J. Granlund, A. Discacciati, F. Hjern, P. T. Schmidt, O. Olén et al.
Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life. BJS 2019; 106: 805-805.
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. BJS 2019; 106: 728-728.
Authors: B. Shinkins, J. N. Primrose, S. A. Pugh, B. D. Nicholson, R. Perera, T. James et al.
Authors: I. S. Reynolds, S. J. Furney, E. W. Kay, D. A. McNamara, J. H. M. Prehn, J. P. Burke et al.
Randomized clinical trial
Randomized clinical trial of liposomal bupivacaine transverse abdominis plane block versus intrathecal analgesia in colorectal surgery. BJS 2019; 106: 692-699.
Authors: D. T. Colibaseanu, O. Osagiede, A. Merchea, C. T. Ball, E. Bojaxhi, J. K. Panchamia et al.
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer. BJS 2019; 106: 922-929.
Authors: B. J. Quiram, J. Crippa, F. Grass, J. K. Lovely, K. T. Behm, D. T. Colibaseanu et al.